Loading...
By Kelly Young
Edited by David G. Fairchild, MD, MPH, and Jaye Elizabeth Hefner, MD
New gout guidelines from the American College of Physicians notably don't include a recommendation to lower serum uric acid levels below 357 µmol/L (6 mg/dL), in contrast with the American College of Rheumatology's 2012 guidelines.
In the Annals of Internal Medicine, the ACP notes that some patients below this threshold may still have symptoms. A member of the guideline committee writes in an editorial, "The [committee] finds it difficult when it cannot endorse a widely disseminated recommendation from a fellow professional society because of a lack of adequate supporting evidence."
Among the ACP's recommendations:
Corticosteroids, nonsteroidal anti-inflammatory drugs, and colchicine are recommended for flare management.
When using colchicine, lower doses (1.2 mg, then 0.6 mg 1 hour later) are recommended since they are as effective as higher doses and have fewer side effects.
Long-term therapy to lower uric acid levels is not usually recommended after single or infrequent attacks.
To diagnose acute gout, clinicians should use synovial fluid analysis when the joint can be aspirated without patient discomfort by a knowledgeable clinician and when available resources can detect urate crystals.
Comment
LINK(S):
Gout management guidelines in the Annals of Internal Medicine (Free)
Evidence review on management (Free)
Gout diagnosis guidelines in the Annals of Internal Medicine (Free)
Evidence review on diagnosis (Free)
Annals of Internal Medicine editorial criticizing lack of treat-to-target recommendation (Subscription required)
Annals of Internal Medicine editorial justifying not including treat-to-target recommendation (Subscription required)
Background: Physician's First Watch coverage of 2012 gout guidelines from American College of Rheumatology (Free)